» Articles » PMID: 28002473

Role of Occult and Post-acute Phase Replication in Protective Immunity Induced with a Novel Live Attenuated SIV Vaccine

Overview
Journal PLoS Pathog
Specialty Microbiology
Date 2016 Dec 22
PMID 28002473
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

In order to evaluate the role of persisting virus replication during occult phase immunisation in the live attenuated SIV vaccine model, a novel SIVmac239Δnef variant (SIVrtTA) genetically engineered to replicate in the presence of doxycycline was evaluated for its ability to protect against wild-type SIVmac239. Indian rhesus macaques were vaccinated either with SIVrtTA or with SIVmac239Δnef. Doxycycline was withdrawn from 4 of 8 SIVrtTA vaccinates before challenge with wild-type virus. Unvaccinated challenge controls exhibited ~107 peak plasma viral RNA copies/ml persisting beyond the acute phase. Six vaccinates, four SIVmac239Δnef and two SIVrtTA vaccinates exhibited complete protection, defined by lack of wild-type viraemia post-challenge and virus-specific PCR analysis of tissues recovered post-mortem, whereas six SIVrtTA vaccinates were protected from high levels of viraemia. Critically, the complete protection in two SIVrtTA vaccinates was associated with enhanced SIVrtTA replication in the immediate post-acute vaccination period but was independent of doxycycline status at the time of challenge. Mutations were identified in the LTR promoter region and rtTA gene that do not affect doxycycline-control but were associated with enhanced post-acute phase replication in protected vaccinates. High frequencies of total circulating CD8+T effector memory cells and a higher total frequency of SIV-specific CD8+ mono and polyfunctional T cells on the day of wild-type challenge were associated with complete protection but these parameters were not predictive of outcome when assessed 130 days after challenge. Moreover, challenge virus-specific Nef CD8+ polyfunctional T cell responses and antigen were detected in tissues post mortem in completely-protected macaques indicating post-challenge control of infection. Within the parameters of the study design, on-going occult-phase replication may not be absolutely required for protective immunity.

Citing Articles

The Impact and Effects of Host Immunogenetics on Infectious Disease Studies Using Non-Human Primates in Biomedical Research.

Berry N, Mee E, Almond N, Rose N Microorganisms. 2024; 12(1).

PMID: 38257982 PMC: 10818626. DOI: 10.3390/microorganisms12010155.


Adjuvanted recombinant zoster vaccine in adult autologous stem cell transplant recipients: polyfunctional immune responses and lessons for clinical practice.

Stadtmauer E, Sullivan K, El Idrissi M, Salaun B, Alonso Alonso A, Andreadis C Hum Vaccin Immunother. 2021; 17(11):4144-4154.

PMID: 34406911 PMC: 8828160. DOI: 10.1080/21645515.2021.1953346.


Immune responses to the adjuvanted recombinant zoster vaccine in immunocompromised adults: a comprehensive overview.

Dagnew A, Vink P, Drame M, Willer D, Salaun B, Schuind A Hum Vaccin Immunother. 2021; 17(11):4132-4143.

PMID: 34190658 PMC: 8827627. DOI: 10.1080/21645515.2021.1930846.


The Adjuvanted Recombinant Zoster Vaccine in Adults Aged ≥65 Years Previously Vaccinated With a Live-Attenuated Herpes Zoster Vaccine.

Dagnew A, Klein N, Herve C, Kalema G, Di Paolo E, Peterson J J Infect Dis. 2020; 224(7):1139-1146.

PMID: 32103273 PMC: 8514183. DOI: 10.1093/infdis/jiaa083.


Variable Baseline Endogenous Retrovirus (PcEV) Expression Is Upregulated in Acutely SIV-Infected Macaques and Correlated to STAT1 Expression in the Spleen.

Atangana Maze E, Ham C, Kelly J, Ussher L, Almond N, Towers G Front Immunol. 2019; 10:901.

PMID: 31156613 PMC: 6529565. DOI: 10.3389/fimmu.2019.00901.


References
1.
Lim S, Rogers T, Chan T, Whitney J, Kim J, Sodroski J . TRIM5alpha Modulates Immunodeficiency Virus Control in Rhesus Monkeys. PLoS Pathog. 2010; 6(1):e1000738. PMC: 2809762. DOI: 10.1371/journal.ppat.1000738. View

2.
Mansfield K, Lang S, Gauduin M, Sanford H, Lifson J, Johnson R . Vaccine protection by live, attenuated simian immunodeficiency virus in the absence of high-titer antibody responses and high-frequency cellular immune responses measurable in the periphery. J Virol. 2008; 82(8):4135-48. PMC: 2292994. DOI: 10.1128/JVI.00015-08. View

3.
Ferguson D, Mattiuzzo G, Ham C, Stebbings R, Li B, Rose N . Early biodistribution and persistence of a protective live attenuated SIV vaccine elicits localised innate responses in multiple lymphoid tissues. PLoS One. 2014; 9(8):e104390. PMC: 4146474. DOI: 10.1371/journal.pone.0104390. View

4.
Berry N, Stebbings R, Ferguson D, Ham C, Alden J, Brown S . Resistance to superinfection by a vigorously replicating, uncloned stock of simian immunodeficiency virus (SIVmac251) stimulates replication of a live attenuated virus vaccine (SIVmacC8). J Gen Virol. 2008; 89(Pt 9):2240-2251. DOI: 10.1099/vir.0.2008/001693-0. View

5.
Stone M, Ma Z, Genesca M, Fritts L, Blozois S, McChesney M . Limited dissemination of pathogenic SIV after vaginal challenge of rhesus monkeys immunized with a live, attenuated lentivirus. Virology. 2009; 392(2):260-70. PMC: 2754392. DOI: 10.1016/j.virol.2009.06.052. View